RENALYTIX PLC LS-0025 (2O9) - Total Liabilities
Based on the latest financial reports, RENALYTIX PLC LS-0025 (2O9) has total liabilities worth €11.10 Million EUR (≈ $12.98 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See RENALYTIX PLC LS-0025 (2O9) liquidity interval to measure how many days the company can operate on defensive assets alone.
RENALYTIX PLC LS-0025 - Total Liabilities Trend (2022–2025)
This chart illustrates how RENALYTIX PLC LS-0025's total liabilities have evolved over time, based on quarterly financial data. Check RENALYTIX PLC LS-0025 liquidity resilience to evaluate the company's liquid asset resilience ratio.
RENALYTIX PLC LS-0025 Competitors by Total Liabilities
The table below lists competitors of RENALYTIX PLC LS-0025 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Able View Global Inc. Class B Ordinary Shares
NASDAQ:ABLV
|
USA | $26.78 Million |
|
Touchstone Exploration Inc
TO:TXP
|
Canada | CA$164.80 Million |
|
MBL Infrastructure Limited
NSE:MBLINFRA
|
India | Rs19.94 Billion |
|
Mangalam Organics Limited
NSE:MANORG
|
India | Rs4.21 Billion |
|
Bonia Corporation Bhd
KLSE:9288
|
Malaysia | RM237.11 Million |
|
Sangsangin Industry Co. Ltd.
KQ:101000
|
Korea | ₩29.02 Billion |
|
PGF Polska Grupa Fotowoltaiczna SA
WAR:PGV
|
Poland | zł29.52 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down RENALYTIX PLC LS-0025's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of RENALYTIX PLC LS-0025.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -9.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how RENALYTIX PLC LS-0025's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for RENALYTIX PLC LS-0025 (2022–2025)
The table below shows the annual total liabilities of RENALYTIX PLC LS-0025 from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | €13.10 Million ≈ $15.32 Million |
-18.63% |
| 2024-06-30 | €16.10 Million ≈ $18.82 Million |
-31.96% |
| 2023-06-30 | €23.66 Million ≈ $27.66 Million |
+21.61% |
| 2022-06-30 | €19.46 Million ≈ $22.75 Million |
-- |
About RENALYTIX PLC LS-0025
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from … Read more